Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Antengene presents R&D at Evercore Summit
Business clinical data update

Antengene presents R&D at Evercore Summit

Analysis based on 6 articles · First reported Jul 20, 2026 · Last updated Aug 19, 2026

Sentiment
40
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The presentation of positive clinical data and new platform technologies is likely to bolster investor confidence in Antengene's pipeline and future prospects. The company's stock may experience positive sentiment, though the impact is moderate given the early-stage nature of the data and the event being a conference presentation.

Biotechnology Pharmaceuticals
Event Summary

Antengene Corporation Limited, a commercial-stage global biotech company listed on the China — Hong Kong Stock Exchange (SEHK: 6996.HK), presented key research and development highlights at the Evercore 2nd China Biotech Summit. The company disclosed updated clinical data from the Phase II CLINCH study of ATG-022, a CLDN18.2 antibody-drug conjugate, showing objective response rates of 42.4% and 46.7% in the 2.4 mg/kg and 1.8 mg/kg dose cohorts, respectively, with a favorable safety profile. Antengene also showcased its proprietary TriGager TCE platform and introduced ATG-207, a first-in-class bifunctional fusion protein for autoimmune diseases. The company highlighted its progress in advancing ATG-022 across multiple lines of gastric cancer treatment and its broad TCE pipeline, including out-licensed candidates to UCB and K2 Therapeutics.

Key Actions
90 Antengene presented updated clinical data
70 Antengene showcased TriGager platform
60 Antengene introduced ATG-207
50 Antengene out-licensed drug candidates UCB
50 Antengene out-licensed drug candidates K2 Therapeutics
Entities Involved
priv
Antengene
Antengene is the central entity, presenting its clinical data and pipeline advancements, which could enhance its valuation and competitive position.
Importance 100.0 Sentiment 60.0
cnt
China
China is a key market where Antengene conducts clinical trials and has regulatory approvals, affecting its commercial prospects.
Importance 40.0 Sentiment 30.0
stock
UCB
UCB is a partner that has licensed an Antengene TCE candidate, benefiting from potential pipeline expansion.
Importance 30.0 Sentiment 20.0
priv
K2 Therapeutics
K2 Therapeutics has licensed an Antengene TCE candidate, gaining access to a promising asset.
Importance 30.0 Sentiment 20.0
cnt
Australia
Australia is a site for Antengene's clinical trials and a market where its lead drug is approved.
Importance 30.0 Sentiment 20.0
priv
Evercore
Evercore hosted the summit, providing a platform for Antengene's presentation, but its role is peripheral.
Importance 20.0 Sentiment 10.0
loc
China — Hong Kong
China — Hong Kong is the listing venue for Antengene and a market where its drug is approved.
Importance 20.0 Sentiment 15.0
cnt
Taiwan
Taiwan is a market where Antengene's drug is approved, contributing to its commercial footprint.
Importance 15.0 Sentiment 10.0
cnt
South Korea
South Korea is a market with drug approval and insurance coverage, supporting Antengene's sales.
Importance 15.0 Sentiment 10.0
cnt
Singapore
Singapore is a market with drug approval and insurance coverage, contributing to Antengene's revenue.
Importance 15.0 Sentiment 10.0
cnt
Indonesia
Indonesia is a market where Antengene's drug is approved, broadening its market access.
Importance 10.0 Sentiment 5.0
priv
MPM BioImpact
MPM BioImpact is the founder of K2 Therapeutics, indirectly involved through the licensing deal.
Importance 10.0 Sentiment 5.0
loc
China — Macau
China — Macau is a smaller market where Antengene's drug is approved.
Importance 10.0 Sentiment 5.0
cnt
Malaysia
Malaysia is a market where Antengene's drug is approved, expanding its reach.
Importance 10.0 Sentiment 5.0
cnt
Thailand
Thailand is a market where Antengene's drug is approved, adding to its commercial presence.
Importance 10.0 Sentiment 5.0
Relationships
China related ↔ Australia
China related ↔ Evercore
China adversary ↔ Taiwan China claims Taiwan as its own territory and frequently conducts aggressive military blockade drills, refusing to rule o
China strategic partners ↔ South Korea China views South Korea as a vital strategic and economic partner, with relations fully restored in 2026 to foster coope
China related ↔ Singapore
Australia related ↔ Taiwan
Australia related ↔ South Korea
Australia related ↔ Singapore
Taiwan related ↔ South Korea
Taiwan related ↔ Singapore
South Korea related ↔ Singapore
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.